Anti-tumour activity of TCNU in a panel of transplantable murine colon tumours.
The novel nitrosourea, 1-(2-chloroethyl)-3-[2-(dimethylaminosulphonyl)ethyl]-1-nitrosoure a (TCNU) is active against a panel of three transplantable murine adenocarcinomas of the colon of varying growth characteristics and morphology (MAC system). It shows greater activity than previously tested nitrosoureas in this system and the routes of administration of TCNU do not significantly alter its anti-tumour activity. These data suggest that TCNU may be useful in the management of large bowel cancer as the MAC system has been previously shown to be a good model of human disease.
Bibby
M C
MC
Clinical Oncology Unit, University of Bradford, West Yorkshire, U.K.
Double
J A
JA
Morris
C M
CM
D000230:Adenocarcinoma / Q000188:drug therapy*; D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D008297:Male; D051379:Mice; D009368:Neoplasm Transplantation; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D013654:Taurine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D013654:Taurine; C052991:1-(2-chloroethyl)-3-(2-(dimethylaminosulfonyl)ethyl)-1-nitrosourea